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he goal of this panel was to identify key issues
with regard to addressing bias, credibility,
and the quality of pharmacoeconomic evaluations.
Its specific objectives were to:
• identify and prioritize the key issues associated
with reducing bias and increasing credibility
and quality of pharmacoeconomic evaluations;
• identify a plan of action to resolve these issues;
• recommend next steps.
 
Background and Context
 
Bias, quality, and credibility are long-term re-
search issues addressed by experts in many fields.
Like other disciplines, the field of health econom-
ics continues to evolve and challenge itself in this
regard. Improvements in this field of research ne-
cessitate support and adhesion to the highest qual-
ity work and integrity, promotion of continuous
quality enhancement, and open dialogue.
Definition of bias in the field of health eco-
nomic research refers to a meaning beyond the
Stanley and Campbell [1,2] statistical concept
(i.e., as a threat to validity). Bias is also an ethical
issue dealing with disclosure and conflict of inter-
est. The following definition of bias was proposed
by the Task Force on Principles for Economic
Analysis of Healthcare Technology in 1995 [3]:
“A range of factors that systematically influence
the measures undertaken independent of the stud-
ied intervention; a tendency, intentional or unin-
tentional, to inappropriately or unfairly favor one
or more of the interventions being evaluated.”
Resolution of bias, quality, and credibility issues
in health economics is complicated by a host of fac-
tors, especially the variety of stakeholders and their
unique perspectives and information needs. These
stakeholders include users of research (managed
care organizations, governments, payers, and pro-
viders) and the producers of research (government
agencies, pharmaceutical firms, payers and provid-
ers, academics, consultants, and foundations).
The objectives of this panel were to address the
issues of bias, quality, and credibility of health
economic research from the perspective of both
producers and users of these data, with patient
care as the underlying concern. The scope of the
panel’s deliberation included public dissemina-
tion of research data, methods to improve quality,
minimize bias, and thus enhance credibility of
health economic studies. Methodology issues are
elsewhere. The panel anticipates that as advance-
ments are made over time, concerns over bias,
quality, and credibility of health economic re-
search will diminish.
 
Problem Statement
 
Multiple published studies have criticized the
rigor, relevance, objectivity, methods, and reports
produced within the health economic research do-
main [4–12]. Consequently, health economic re-
search findings are not used as extensively as they
could be and rational decision processes about the
efficient use of healthcare resources may not be
fully informed. Ultimately, care for patients and
populations may be adversely affected. In this con-
text, there is a need for continued improvement in
the quality of economic research conducted.
 
Issues
 
The panel identified the following three key issues:
1. Quality: Are the best methods being used?
2. Bias: Whether it is real or perceived, how do
we deal with it?
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3. Credibility: Do we have a problem with believ-
ability or with relevance?
 
Quality
 
Health economics is a relatively new science with-
out strong consensus on all methods. There is a
need to develop consensus on methodology for
quality issues to be resolved. The multidisciplinary
nature of this field of research makes peer identifi-
cation for manuscript review difficult. In addition,
there is a lack of consensus on evaluation criteria,
rendering the peer review process difficult.
 
Bias
 
Bias can be divided into “intentional” bias and
“unintentional” or “subtle” bias, which includes
design flaws and inappropriate conclusions irre-
spective of the medical interventions under study.
Bias can be related to the underpowered nature of
many clinical and database studies, which would
require much larger samples. There is a perception
that financial sponsorship will bias study results.
However, despite objectivity problems, industry is
still the major funding body for healthcare eco-
nomic information. Withholding negative findings
and failure to submit data to public scrutiny can
bias the literature and applications of research
data that are disseminated. There are few occa-
sions when circumstances would make the with-
holding of results acceptable [13].
 
Credibility
 
The relevance of health economic research data is
questioned by decision-makers with respect to
populations studied and the disconnect between
decision-maker’s criteria (business decisions under
risk or uncertainty where majority rules) and
methodologist’s concerns (scientific standards seek-
ing statistical significance). Stakeholders have dif-
ferent objectives. Methods are geared to societal
decision-making, but practical applications are at
a different level. In addition, decisions have to be
made right away and cannot wait for the develop-
ment of better methods. Some groups and journals
such as the 
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 [14]
have questioned the credibility of health economic
analyses and restricted the dissemination of data.
The ownership of health economic data must be
defined, as well as access to this information.
Health economic tools are expected to be em-
ployed to optimize use of the resources of society,
but few decision-makers use them that way.
 
Recommendations and Next Steps
 
The following recommendations will improve the
quality and credibility of health economic re-
search. These recommendations pertain to these
domains:
• design and research practices;
• sponsorship;
• publication and dissemination;
• role of professional societies and organiza-
tions;
• development of study methods and ethics stan-
dards;
• follow-up conference.
 
Design and Research Practices
 
Researchers should design and conduct studies us-
ing the best available practices consistent with the
study objectives. Methods should be specified in
advance and should be reported explicitly and
transparently. Health economic studies should
generally follow ethical Good Clinical Practices
provisions such as those described by the Ameri-
can Federation of Clinical Research (AFCR, Good
Clinical Practices) or other authoritative bodies.
Prospectively designed pilot studies are essential
for the evaluation of feasibility and the planning
of future research. In addition, studies should not
be terminated early in an attempt to hide un-
wanted health economic results of potential inter-
est. Base case assumptions should be clear, and the
sensitivity analyses should include conservative as-
sumptions for the new technology being assessed.
 
Sponsorship
 
Full disclosure of any financial relationships that
authors and speakers have linking them directly or
indirectly to the interventions under study should
be listed. Sponsored research should have a writ-
ten protocol agreed to by researchers and spon-
sors in advance. Unanticipated issues should be
handled by mutually agreed protocol amend-
ments. Access to relevant documents and data,
project control, presentation, and publication
rights should be defined in advance in the contract
[15]. The contract would reflect the code of ethics
recommended by this panel.
 
Publication and Dissemination
 
Authorship should conform to generally recog-
nized practices among the peer research commu-
nity. Research data, given full disclosure, trans-
parency, and sufficient information to replicate
the study, should be judged on the merits of its
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content. One or more authors should be receptive
to and available for reader inquiries in those cases
where it is clearly not practical or possible to pro-
vide all information necessary for replication of
the study within a manuscript. Publication deci-
sions by journals should use the same criteria for
evaluating merit of health economic studies that
are used for other types of manuscripts, and
should not preclude publication of health eco-
nomic work due solely to funding arrangements
or author affiliations. Published reports should
address the criteria established by experts and be
completely transparent to facilitate evaluation,
comparison, or reproduction.
Mandating full publication rights in a code of
ethics for health economic research remains an
area of debate among panel members. Certain
members believe that this issue is at the heart of
bias and credibility problems, and they advocate
full publication rights for contractors performing
health economic research. Other panel members
anticipate that mandatory rights in certain health
economic studies could be problematic. Organiza-
tions, industries, or government bodies using con-
tractors to perform studies are not likely to allow
full publication rights for their services.
 
Role of Professional Societies and Organizations
 
A professional society such as the International
Society for Pharmacoeconomics and Outcomes
Research (ISPOR), the Association for Health Ser-
vices Research (AHSR), or the Society for Medical
Decision-Making (SMDM) should consider devel-
oping a code of ethics for health economic re-
searchers. Those professional societies need to col-
laborate on education and best practices for the
benefit of association members, the journal com-
munity, and research users, and to improve qual-
ity, reduce bias, and enhance credibility of health
economic research. Professional societies should
also help journal editors identify peer reviewers
and advise on their review procedures. A founda-
tion to address these ideas may be in order. ISPOR
and similar bodies should also publicize awards
for high-quality research, including student or fel-
lowship awards.
The concept of an independent body that
would provide confidential advice and would cer-
tify voluntarily submitted health economic study
designs and reports deserves further discussion.
This body could be a quasi-public organization
that discloses all its financial relationships. Impor-
tantly, a similar body might also investigate means
of evaluating health economic research for contin-
uous quality improvement and development of the
field.
 
Development of Study Methods and Ethics Standards
 
In the near future, clear best methodological and
ethical practice statements should be developed
and disseminated. Meetings with journal editors
and users should be organized to educate and of-
fer assistance to stakeholders. Specific recommen-
dations are:
• Researchers should design and conduct studies
using the best practices consistent with the
study objectives. Methods should be specified
in advance, explicitly and transparently re-
ported.
• Health economic studies should generally fol-
low the ethical Good Clinical Practices provi-
sions described by authoritative organizations
such as the American Federation of Clinical
Research.
• Authorship should conform to generally recog-
nized practices among the peer research com-
munity.
• Full disclosure of financial relationships of au-
thors and speakers should be listed.
 
Follow-Up Conference
 
A conference similar to this one should be con-
vened in 2 years to review progress made as a re-
sult of these deliberations. ISPOR should work
with other societies and organizations to further
explore all the other recommendations made by
the panel that require additional thought.
In addition to the above recommendations,
ISPOR should develop the following activities:
• Establish a code of ethics addressing among
other issues the use of appropriate methodol-
ogy, reproducibility, publication rights, and
disclosure of potential conflicts of interest. In-
ternal distribution and acceptance should be
sought in the coming year, with subsequent ex-
ternal promotion.
• Create an office to continue work on the issues
raised by the panel, to coordinate collaborative
efforts with other organizations, to provide
regular commentary and input, and to facili-
tate the exchange of ideas in the ISPOR jour-
nal, 
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• Disseminate and increase exposure of informa-
tion related to awards obtained for high-qual-
ity research including annual meeting presenta-
tions, journal articles, and student fellowships.
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• Establish a working relationship and coordi-
nate regular meetings with the Food and Drug
Administration (FDA) to develop health eco-
nomic guidelines to address concerns related to
bias, quality, credibility, and ethics.
 
Summary
 
Criticism of health economic research has resulted
in limited utilization of this data by decision-mak-
ers and end-users, potentially affecting care for
populations. A number of recommendations were
proposed by the panel to address the issues of
bias, quality, and credibility of health economic
research from the perspective of both producers
and users of these data with patient care as the un-
derlying concern. Suggestions include design and
research practice, sponsorship, publication and
dissemination of research data, and the role of
professional associations and organizations.
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